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Since Hachinski et al [1] proposed the term multi-infarct
dementia to describe dementia complicating ischemic
vascular disease, numerous other descriptors have been
used to encompass the heterogeneous clinical and etiolog-
ical spectrum of cognitive impairment due to cerebrovascu-
lar disease (CVD). These include vascular dementia (VaD),
vascular cognitive impairment (VCI), subcortical (ischemic)
vascular dementia, and vascular cognitive disorders (VCDs),
variably diagnosed according to multiple different guide-
lines or protocols [2–14], some agreed by national
institutions or research networks, for example, Alzheimer’s
Disease Diagnostic and Treatment Centers [11], Interna-
tional Statistical Classification of Diseases, 10th revision
[15], the National Institute of Neurological Disorders and
Stroke (NINDS)–Association Internationale pour la Re-
cherche et l’Enseignement en Neurosciences [16], and Diag-
nostic and Statistical Manual of Mental Disorders, fourth
and fifth editions (DSM-4 and DSM-5; [17,18]).
Studies comparing some of these protocols have shown
they are not readily interchangeable [19–21]. After the
commencement of the Vascular Impairment of Cognition
Classification Consensus Study phase 1 (VICCCS-1), the
American Heart Association/American Stroke Association
(AHA/ASA) published a statement on vascular
contributions to cognitive impairment and dementia [22].
This supported the use of assessment protocols previously
published by NINDS–Canadian Stroke Network (CSN)
[13]. There have been other recent contributions to this field
from the International Society of Vascular Behavioral and
Cognitive Disorders (VASCOG) [23] and the DSM-5 [18].
The level of take up of these recent guidelines is still unclear.
Only those published during VICCCS-1, before commence-
ment of VICCCS-2, could be included for consideration in
the present study [22,24].
The aim of VICCCS was to achieve broad international
consensus on diagnosis of VCI, through participation of a
large pool of international researchers and clinicians in an
iterative survey using the Delphi approach. After two initial
survey rounds, the study was separated into two phases:
VICCCS-1, addressing key concepts in our understanding
and terminology of cognitive impairment resulting from
CVD [25], and VICCCS-2, focusing on the formulation of
practical guidelines for diagnosis.
The VICCCS-1 achieved broad consensus on concepts of
VCI. It supported the use of “mild” and “major” subdivisions
of the severity of impairment, aligning with the revised ter-
minology in the DSM-5. VICCCS-1 participants concluded
that attempts to separate mild VCI into further subtypes ac-
cording to affected cognitive domains were at present pre-
mature but agreed that this should be an area of future
research. VICCCS-1 agreed (Fig. 1, reproduced from [25])
that the major forms of VCI (VaD) should be classified
into four main subtypes: (i) post-stroke dementia (PSD);
(ii) subcortical ischemic vascular dementia (SIVaD); (iii)multi-infarct (cortical) dementia (MID); and (iv) mixed de-
mentias (further subdivided according to additional neuro-
degenerative pathologies). Framed by these concepts,
VICCCS-2 used the same Delphi methodology to agree
diagnostic guidelines on determination of severity of VCI
and discrimination of subtypes.2. Methods
Participants in VICCCS-1 [25] were invited to participate
in VICCCS-2 (Supplementary Fig. 1). Although 149 initially
agreed to participate, only approximately half were active
and committed respondents in three or more rounds, with
low attrition and little variation in participation throughout
the six rounds (65–79 participants in each round, a mean of
72). Of the active participants, 63%–75% of participants
(mean 68%) were clinicians with direct involvement in clin-
ical assessment or health service patient care. The remainder
were nonclinical (i.e., supporting clinical work technically or
otherwise, but not involved in clinical decision-making, or
predominantly involved in research). Individual round repre-
sentation is provided in Supplementary Table 1.2.1. Data collection
We used the Delphi method, an iterative, multistaged se-
ries of structured questionnaires with feedback of anony-
mized responses and progressive refinement of questions
to reach consensus [26]. The process was co-ordinated by
a nonparticipating researcher (O.A.S). Anonymization of re-
sponses facilitated free expression of opinion throughout the
study. Feedback of summary responses after each round
informed subsequent questions and allowed unbiased evolu-
tion of group judgment. A threshold of two-thirds agreement
was chosen to signify consensus [27] for issues refined iter-
atively through multiple rounds, as in VICCCS-1 [25]. For
issues where this threshold was not reached, we present
the summary data including the view that was most strongly
supported. A summary of topics covered in each Delphi
round is presented in Fig. 2. The first two rounds were
used to select from previous publications those diagnostic
criteria deemed most valuable as a basis for further discus-
sion. These provided main themes addressed in the four sub-
sequent rounds (November 2012–September 2013).
Consensus views from topics addressed in VICCCS-1
were used in discussions.3. Results
3.1. VICCCS foundation rounds and VICCCS-2 rounds 1
and 2
In the two foundation rounds of VICCCS, the consensus
view (94% of respondents) was that none of the current diag-
nostic protocols was fully fit for purpose and that formula-
tion of improved assessment criteria for VCI was a
VCI
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Fig. 1. Revised conceptualization of VCI in VICCCS. Subtypes of VCI are divided according to level of VCI into mild VCI and major VCI (VaD). Mild VCI is
not further subdivided at this time. Major VCI (VaD) is classified into four main subtypes as depicted. The 6-month temporal basis (denoted by the dashed box)
for cognitive decline after stroke differentiates post-stroke dementia (PSD) from other forms of major VCI (VaD). PSD and mixed dementias are further delin-
eated if a comorbid neuropathology is present (AD and DLB are given as examples, with # denoting other possible combinations). Subcortical ischemic vascular
dementia or MID subtype cases were with these specific types of dementia alone; however cases also presenting with any other neurodegenerative pathology
would then be categorized as mixed dementias (dashed arrows) according to the comorbidities present. Abbreviations: AD, Alzheimer’s disease; DLB, dementia
with Lewy bodies; MID, multi-infarct (cortical) dementia; PSD, post-stroke dementia; VaD, vascular dementia; VCI, vascular cognitive impairment; VICCCS,
Vascular Impairment of Cognition Classification Consensus Study.
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researcher-led [2,6,7,11–14,16,28–30] and organization-
based diagnostic criteria/protocols that were critiqued by
the participants, are provided as Supplementary Material.
Participants selected their preferred criteria of the six pre-
sented (fourwere chosen as the best starting points inVICCCS
foundation rounds [6,12,13,31] and two that were published
during VICCCS-1 could therefore be critiqued in VICCCS-2
[22,24]). Of these six, the AHA/ASA Scientific Statement:
vascular contributions to cognitive impairment and dementia
[22], henceforth referred to as AHA/ASA, was the first prefer-
ence of the highest proportion of respondents (41%), followed
byNINDS-CSN [13] (25%). The AHA/ASA does not provide
assessment protocols but refers to the recommendations made
in the NINDS-CSN. These guidelines provided the basis for
further discussion and elaboration.
According to most respondents (65%), VICCCS-2 aimed
to provide a single set of diagnostic guidelines for clinical
and research use. Agreed objectives were to develop a clear
and efficient protocol that was simple to use and would yield
readily interpretable results, allowing discrimination of VCI
subtypes and severity.3.2. VICCCS-2 rounds 3–6
3.2.1. Measure of severity—differentiating between mild
and major VCI
In VICCCS-1 round 4, participants considered the cogni-
tive domains that needed assessment to measure the severityof VCI. These were reviewed in VICCCS-2 round 3, in
which 94% agreed that the core domains for assessment
should be executive function, attention, memory, language,
and visuospatial function. The domains of learning, neuro-
psychiatry, and social cognition should be treated as
optional, outside of the core assessment, unless and until
there is stronger evidence for their inclusion. No other do-
mains (including abstraction, agnosia, emotionality, praxis,
and processing or psychomotor speed) were supported as
core domains; for some, respondents thought there were
insufficient tools for assessment (e.g., apraxia that features
in NINDS-CSN: 80% of respondents).
Eighty-one percent of VICCCS-1 respondents felt that
the differentiation between mild and major VCI (VaD)
should be based on the number of domains affected and
that both instrumental activities of daily living (IADLs)
and activities of daily living (ADLs) were necessary deter-
minants. In VICCCS-2 round 3, a consensus (85%) defini-
tion was achieved for mild VCI: impairment in at least one
cognitive domain, and mild to no impairment in IADL/
ADL, respectively (independent of the motor/sensory
sequelae of the vascular event). In rounds 3 and 4, several
definitions were considered for major VCI (VaD), but no
overall majority was achieved for any one option. On
further examination of the various choices, 71% had cho-
sen a definition that included the word “severe” and 73%
had chosen an option with “at least one cognitive domain”
(rather than “at least two cognitive domains”). These ob-
servations were presented to the participants in round 5,
•Use and crique of currently available criteria
•Vote for which criteria should be used to base discussion upon in VICCCS
VICCCS Foundaon surveys
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•Key factors that make a criterion clinically operaonal
VICCCS-2 Round 1 (R1)
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•Iniate discussion of operaonal consideraons of assessments: me-frame; 
domains; differenang between Mild VCI and Major VCI (VaD)
•Major VCI subgroups and use of 'probable & possible' categories
•Discuss category of 'unstable VCI' and the role of aphasia in diagnosis
VICCCS-2 Round 2 (R2)
•Present R2 results and work toward a structure of diagnosc assessments: 
domains; differenang between Mild VCI and Major VCI (VaD); NINDS-CSN 
crique
•Iniate incorporang temporal relaonships in diagnosis
•Iniate the role of imaging in diagnosis
•Present R2 results of 'unstable VCI' - discuss types of assessment & me-frames
•Present R2 results of the role of aphasia in diagnosis 
VICCCS-2 Round 3 (R3)
•Present R3 results  of working toward a structure of diagnosc assessments
•Present R3 results differenang between Mild VCI and Major VCI (VaD) -
connue discussion of the definion of Major VCI (VaD)
•Present R3 results of incorporang temporal relaonships - address Mul-Infarct 
Demena (MID)
•Present R3 results  of the role of imaging - discuss 'possible or probable' terms
•Present R3 results of the risk of VCI - finalize the me-frame of consideraon
VICCCS-2 Round 4 (R4)
•Present R4 results differenang between Mild VCI and Major VCI (VaD)
•Finalize MID in terms of temporal relaonship
•Finalize use of 'possible and probable' terms
VICCCS-2 Round 5 (R5)
•Present R5 results differenang between Mild VCI and Major VCI (VaD) - finalize 
discussion of the definion of Major VCI (VaD)
•Survey confidence in current assessment tools of ADL
VICCCS-2 Round 6 (R6)
Fig. 2. Summary of topics addressed in each Delphi survey round. Abbreviations: DLB, dementia with Lewy bodies; NINDS-CSN, National Institute of Neuro-
logical Disorders–Canadian Stroke Network; PSD, post-stroke dementia; VaD, vascular dementia; VCI, vascular cognitive impairment; VICCCS, Vascular
Impairment of Cognition Classification Consensus Study.
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favored definitions from the previous round. There was
60% support for the major VCI (VaD) definition: severe
deficits in at least one cognitive domain (other deficits
may be present in multiple domains) and severe disruption
to IADL/ADL (independent of the motor/sensory sequelae
of the vascular event). Consensus-level (67%) support
was obtained for a definition requiring deficits in one
rather than two cognitive domains and for inclusion ofthe descriptor “severe”. Those who did not support the
mandatory inclusion of the descriptor “severe” highlighted
the important issue of people with moderate cognitive
impairment and suggested the use of the term “significant”
to allow greater clinical discretion and flexibility. The
scenario of “. the case of the very bright patient whose
functioning is severely compromised but still does ok
on rudimentary cognitive assessment” was given as an
illustrative example.
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asked to consider an amendment of the definition of major
VCI (VaD) by substitution of “severe” with “significant”,
that is, clinically significant deficits in at least one cognitive
domain (other deficits may be present in multiple domains)
and severe disruption to IADL/ADL (independent of the mo-
tor/sensory sequelae of the vascular event). Fifty-two
percent of participants were in favor, and support for the
most popular definition in round 5—severe deficits in at least
one cognitive domain (other deficits may be present in mul-
tiple domains) and severe disruption to IADL/ADL (inde-
pendent of the motor/sensory sequelae of the vascular
event)—had dropped to 34%. Although our predefined
consensus level (67%) was not reached for any definition
in either round, it was clear that some qualification of the
severity of deficit in at least one cognitive domain was
preferred. Therefore, the proposed definition (representing
the majority view) for major VCI (VaD) is as follows: clini-
cally significant deficits in at least one cognitive domain
(other deficits may be present in multiple domains) and
severe disruption to IADL/ADL (independent of the motor/
sensory sequelae of the vascular event).
3.2.2. Clinical evaluation and time frame for assessment
Recommendations of the NINDS-CSN abbreviated clin-
ical evaluation of VCI were strongly supported by round 3
respondents (86%). However, NINDS-CSN recommenda-
tions differ for research and clinical settings, and most round
2 respondents (77%) thought that the priority should be to
agree a core of assessments for both research and clinical
use, with the option of additional assessments for local use
in either a clinical or research context.
It was agreed that a neuropsychological assessment pro-
tocol for use in a typical clinical diagnostic setting, noting
time pressures and patient group capabilities, should take
60 minutes at most, although optional assessments could
take additional time. The inclusion of all core items in the
NINDS-CSN 60-minute protocol was supported by mostTable 1
NINDS-CSN Neuropsychological assessment supported for use in VICCCS guide
Assessment tool
Animal naming (semantic fluency)
Controlled Oral Word Association (phonemic fluency)
WAIS-III Digit Symbol-Coding (processing speed and activation)
Trail Making Test (processing speed and set shifting)
Revised Hopkins Verbal Learning Test (additional scoring options: strategic
learning; episodic memory; and executive organization)
Rey-Osterrieth Complex Figure Copy (visuospatial)
Boston Naming Test, 2nd Edition, Short Form (visual confrontation naming)
Simple and choice reaction time tasks
Neuropsychiatric Inventory, Questionnaire Version (NPI-Q)
Center for Epidemiological Studies-Depression Scale (CES-D), Short Form
Mini–Mental State Examination (MMSE; Supplementary Material)
Supported tests from the proposed NINDS-CSN [13].
NOTE. 30- or 60-minute protocols are listed with percentage support, where app
test would be necessary for non-English speakers.round 3 respondents. Only the Mini–Mental State Examina-
tion supplementary test was supported by most respondents
(71%). Other supplemental tests—Rey-Osterrieth Complex
Figure, Boston Naming Test, and Digit Symbol-Coding Inci-
dental Learning—did not achieve consensus support for
inclusion. All core and supplementary items in the NINDS-
CSN 30-minute protocol were also supported (Table 1).
3.2.3. The role of aphasia in diagnosis of VCI
VICCCS-2 round 2 respondents agreed (72%) with the
AHA/ASA statement on aphasia: “Severity of aphasia pre-
cludes proper cognitive assessment. However, patients with
documented evidence of normal cognitive function (e.g.,
annual cognitive evaluations) before the clinical event that
caused aphasia could be classified as having probable VaD/
VaMCI.” [22]. In round 4, respondents agreed (96%) on the
qualifying sentence “that the assessment of IADL/ADL
should be made where possible”. Sixty-eight percent of
round 4 participants felt that “probable mild VCI or probable
major VCI” was the appropriate classification of cases with
aphasia when imaging was available and “possible” used in
cases of aphasia when imaging was not available (90%).
3.2.4. Those at risk of VCI
One of the agreed principles in VICCCS-1 [25] was as
follows: “The new VCI construct recognizes the impor-
tance of people who are at risk of VCI, however, their
consideration should be contingent upon the presentation
of a sustained level of impairment even if in a very mild
form as opposed to impairment that can be transient or
revert to normal levels”. Respondents agreed (96%) that
people at risk of VCI should be given greater consideration
for diagnosis if at least 6 months of sustained impairment is
present. Eighty-eight percent also agreed that in those at
risk of VCI, other potential causes of sustained impairment
(e.g., depression or vitamin D deficiency), in addition to the
already agreed exclusions from diagnosis (i.e., drug/
alcohol abuse/dependence within the last 3 months of firstlines
60 minute 30 minute
100% 100%
86% 83%
85% 82%
95% 88% (Supplementary)
75% 79%
80%
93%
96%
86% 84%
71% 71%
71% 75%
licable. Similar word list learning tests to the revised Hopkins verbal learning
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excluded. Caregiver reporting (88%) and clinical observa-
tion (73%) were supported mechanisms to collect this in-
formation. Screening-type assessment (49%) and more
detailed formal assessment (43%) were not supported by
the majority.
3.2.5. Possible and probable terms in VCI and “mixed
dementias” subgroup
3.2.5.1. Top of form
In theAHA/ASA,which served as a starting point to discuss
the use of the terms “possible” and “probable” VCI, only the
categories of “possible”VaDor vascularmild cognitive impair-
ment (VaMCI) allowed the inclusion of other phenotypes (e.g.,
evidence of other neurodegenerative disorders). The AHA/
ASAalso does not provide separate diagnosis or allow delinea-
tion of further subgroups of patients (e.g., the comorbidities
present in mixed dementias). In VICCCS-1, the consensus
was that VCI should contain a standalone umbrella-like sub-
group termed “mixed dementias”. VICCCS-1 participants
also agreed that this subgroup could comprise further group-
ings that included patients with specific combinations of phe-
notypes, each of which would be specifically named where
possible (e.g., VCI–Alzheimer’s disease (AD) if there is evi-
dence of both VCI and AD). Furthermore, it was agreed that
the order of the descriptive phenotypic terms relevant to pa-
tients should attempt to reflect the relative contribution of phe-
notypes present, that is, AD-VCI, orVCI-AD, to the extent that
discrimination was possible.
On consideration of differences between the AHA/ASA
and VICCCS-1, VICCCS-2 round 2 respondents agreed
(92%) that the diagnostic guidelines should attempt to incor-
porate the VICCCS-proposed “mixed dementias” as a sepa-
rate distinct diagnostic subgroup of major VCI, and
“probable” or “possible” are to be used to differentiate the
level of diagnostic evidence to help classify patients for
bothmajorVCI (VaD) subgroups (81%) andmildVCI (70%).
3.2.6. Incorporating temporal relationships in VCI
diagnosis
In AHA/ASA, a clear temporal relationship between a
vascular event and onset of cognitive deficits is required
for a “probable” diagnosis. In VICCCS-1, the definition of
PSD—an agreed subgroup of major VCI (VaD)—required
that cognitive decline develop within 6 months of stroke.
However, temporal relationships were not discussed for
other subtypes of VCI. In VICCCS-2, respondents thought
that a clear temporal relationship between a vascular event
and onset of cognitive deficits should not be an essential
component for diagnosis of mild VCI (77%), SIVaD
(88%), mixed dementias (85%), or MID (74%).
3.2.7. The role of imaging in VCI diagnosis
In VICCCS-2 round 3, the consensus was that imaging
evidence of CVD was essential for diagnosis of majorVCI (VaD) (86%) and mild VCI (79%). In round 4,
although most respondents felt the NINDS-CSN recom-
mendations were possible/appropriate in the respondents’
clinical settings (75% magnetic resonance imaging
[MRI]/81% computed tomography [CT]), 93% thought
that the “acceptable MRI measures” proposed in NINDS-
CSN should be the core recommendation for imaging in
clinical settings, and the “recommended MRI measures”
supported as additional measures for use in either clinical
or research contexts (Table 2 and 3). Several respondents
stated that CT might be insensitive or insufficient to
detect small-vessel disease or evaluate vascular status.
The limitations of CT for VCI are also highlighted in
NINDS-CSN. In round 4, respondents agreed (93%) that
MRI should be the gold-standard imaging for VCI, and
90% agreed that CT should be used only if MRI were not
available or deemed too costly. This would also apply to
cases where MRI is contraindicated. A consensus (68%)
was reached on the use of the term “possible” mild VCI
or major VCI if neither MRI nor CT imaging were avail-
able. Yet 89% felt that “probable” was the appropriate diag-
nostic category if only CT imaging were available.
Majority of support (67%) was not reached for any of the
other “future” imaging methods described in NINDS-CSN,
and the consensus was that none of these is ready for inclu-
sion in clinical diagnosis.
A summary of VICCCS diagnosis guidelines is provided
in Box 1.4. Discussion
The VICCCS-2 has provided new consensus-based
guidelines for diagnosis of mild and major VCI (VaD) as
previously defined [25], with AHA/ASA and NINDS-
CSN guidelines as reference points for discussions. Clin-
ical evaluation and neuropsychological protocols in the
NINDS-CSN were supported for use by VICCCS respon-
dents. The “acceptable MRI measures” outlined in
NINDS-CSN should be the core recommendation for imag-
ing in clinical settings. In terms of assessing severity,
VICCCS diagnosis guidelines specify deficits in at least 1
domain, with clinically significant cognitive deficits of suf-
ficient severity (moderate to severe) and severe deficits in
IADLs/ADLs differentiating major from mild forms. Pa-
tients with PSD, SIVaD, MID, and mixed dementias should
also be subcategorized and any comorbid neurodegenera-
tive disease recorded.4.1. Comparison of VICCCS with recently published
guidelines
The VICCCS was conducted between 2010 and 2013,
which coincided with the development of DSM-5 and
VASCOG criteria for VCDs [23]. VICCCS participants
provided collective feedback on draft DSM-5 proposals
Table 2
MRI and CT imaging recommendations adapted from NINDS-CSN recommendations
Feature Core MRI measures Additional MRI measures CT measures
Brain atrophy  Estimates of atrophy & ventricular size
using the CHS Scale [32]
 Estimates of medial temporal lobe
atrophy using Scheltens Scale [33]
 Quantitative measurement of brain
volume normalized for head size
 Ventricular size
 Hippocampus: medial temporal
atrophy [34]
WMHs  Preferred: ARWMC scale [35]
 Acceptable: CHS WMH Scale [32]
 Quantitative measurement of WMH
volume normalized for head size
 Anatomical mapping also
encouraged [32]
 Diffuse white matter: ARWMC
scale [35]
Infarction  Number and size at specified locations:
- Size (largest diameter): large .
1.0 cm, small 5 3–10 mm
 Location (encourage use of Talairach
Atlas [36] for precision)
B Anatomical locations:
- Supratentorial
- Hemisphere
- Cortical (may include
subcortical)
- Exclusively subcortical white
matter
- Exclusively subcortical gray
matter
B Infratentorial
 All infarcts localized using a standard
approach to generate quantitative
measures of volume and location.
Ideally, identified infarcts would also
be mapped to a common stereotactic
space [32]
 All infarcts should be differentiated
from perivascular spaces (Virchow-
Robin spaces) by CHS criteria (see
Table 3), independently
 Discrete hypodensities
 Cerebrospinal fluid density consistent
with infarction or old hemorrhage:
- Small . 3–1.0 mm
- Large . 1.0 mm
 Acute hemorrhage
 Number, volume, and location—as
core MRI
Hemorrhage  Number and size in each location
 Size (largest diameter)
- Large . 1 cm in diameter
- Microhemorrhage , 1 cm
susceptibility on gradient echo
 Must report lower size limit cutoff,
field strength
 Location—as infarcts
 All lesions localized using a standard
approach to generate quantitative
measures of volume and location.
Ideally, identified lesions would also be
mapped to a common stereotactic
space [32]
Other  Mass lesions, AVMs, extra-axial fluid
collections, malformations, dysplasia,
or any other lesion that might
complicate assessment of
cerebrovascular disease
Abbreviations: ARWMC, age-related white matter change; CHS, Cardiovascular Health Study; AVMs, arteriovenous malformations; CT, computed tomog-
raphy; MRI, magnetic resonance imaging; WMH, white matter hyperintensity.
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a tailored survey developed (by O.A.S), in consultation
with P.S. acting on behalf of the DSM-5 Neurocognitive
Disorders Work Group. VICCCS respondents agreed
that the mild and major terminologies proposed in the
DSM-5 were helpful and should be adopted in VICCCS.
The VASCOG criteria are also aligned with the DSM-5
[23].Table 3
Signal characteristics that differentiate perivascular space and infarcts
Measurable feature T1
Perivascular space Decreased
Ischemic change Isointense (N/A in gray matter)
Infarct Decreased (decreased or isointense in gray matter)
Adapted from NINDS-CSN [13].
NOTE. Differences seen in gray matter from white matter are noted.In terms of assessing severity, both AHA/ASA and
VICCCS specify the same core domains for assessment. In
VASCOG, visuoconstructional-perceptual ability, praxis-
gnosis-body schema, and social cognition are additionally
tested. The definitions of mild VCI are comparable; howev-
er, they are not subcategorized in VICCCS as respondents
felt more evidence was needed. The definition of major
forms of VCI in VICCCS and VASCOG requires deficitsFLAIR/Proton Density T2
Isointense Increased
Increased (N/A in gray matter) Increased (N/A in gray matter)
Increased Increased
Box 1
Summary of the Vascular Impairment of Cognition Classification Consensus Study (VICCCS) diagnosis guidelines
Definitions and diagnosis of VCI:
Clinical evaluation and neuropsychological protocols as provided in the National Institute of Neurological Disorders–
Canadian Stroke Network guidelines are supported (Table 1). Core domains for assessment should include executive
function, attention and memory, as well as language and visuospatial function.
MildVCI: Impairment in at least one cognitive domain andmild to no impairment in instrumental activities of daily living
(IADLs)/activities of daily living (ADLs), respectively (independent of the motor/sensory sequelae of the vascular event).
MajorVCI (VaD):Clinically significant deficits of sufficient severity in at least one cognitive domain (deficits may be present
in multiple domains) and severe disruption to IADLs/ADLs (independent of the motor/sensory sequelae of the vascular event).
Patients given a diagnosis of major VCI (VaD) are subcategorized according to the underlying pathology as appropriate
(Fig. 1). A clear temporal relationship (within 6 months) between a vascular event and onset of cognitive deficits is only
required for a diagnosis of post-stroke dementia (PSD).
Subtypes of major VCI (VaD)y:
Post-stroke dementia:
A patient described as having PSDmay ormay not have presented evidence ofmild cognitive impairment before stroke. The
patient will exhibit immediate and/or delayed cognitive decline that begins within 6 months after a stroke and that does not
reverse. PSD can result from several different vascular causes and changes in the brain. It encompasses dementia that develops
within 6 months of stroke in patients with multiple cortical-subcortical infarcts and strategic infarcts; patients with subcortical
ischemic vascular dementia; and thosewith various formsof neurodegenerative pathology, includingAlzheimer’s disease (AD).
The temporal relationshipbetween the cognitive decline and the strokedifferentiates PSDfromother formsofmajorVCI (VaD).
Mixed dementias:
A standalone umbrella subgroup termed “mixed dementias” includes phenotypes representing each combination between
vascular and neurodegenerative disease, that is, VCI-AD, VCI–dementia with Lewy bodies, and so forth. It is recommended
that a patient is referred to as having “VCI-AD”, for example, according to the clinically probable phenotypes, rather than
the less-specific “mixed dementia”. Where discrimination is possible, the order of terms should reflect the probable relative
contribution of the underlying pathology, that is, AD-VCI or VCI-AD.
Subcortical ischemic vascular dementia:
Small-vessel disease is the main vascular cause of subcortical ischemic vascular dementia. Lacunar infarcts and ischemic
white matter lesions are the main type of brain lesions, which are located predominantly subcortically. This diagnosis in-
corporates the overlapping clinical entities of Binswanger’s disease and the lacunar state.
Multi-infarct dementia:
Multi-infarct dementia is used to indicate the presence of multiple large cortical infarcts and their likely contribution to
the dementia.
“Probable” and “possible”—terms for the availability of evidence:
Magnetic resonance imaging is a “gold-standard” requirement for a clinical diagnosis of VCI. Probable mild VCI or
probable major VCI (VaD) is the appropriate diagnostic category if computed tomography imaging is the only means of
imaging available. Recommendations on imaging from the National Institute of Neurological Disorders–Canadian Stroke
Network should be followed (Table 2 & 3). Possible mild VCI or possible major VCI (VaD) would be appropriate diagnoses
if neither MRI nor computed tomography imaging were available.
In diagnosis of VCI when full clinical assessment of the cognitive impairment resulting from the clinical event is
impaired by aphasia, patients with documented evidence of normal cognitive function (e.g., annual cognitive evaluations)
before the clinical event that caused aphasia could be classified as having probable mild VCI or major VCI (VaD) if imaging
is available, and the assessment of ADLs should bemadewhere possible. If imaging is not available, the classification should
be possible mild VCI or major VCI (VaD).
Those at risk of VCI:
It is recommended that greater consideration for diagnosis be given to peoplewho are at risk of VCI if they present with at
least 6 months of sustained impairment (even if very mild), rather than transient impairment, as identified through caregiver
reporting and clinical observation. All other potential causes of sustained impairment (e.g., depression or vitamin D defi-
ciency, in addition to the already agreed exclusions from diagnosis) should have been excluded.
Exclusions from diagnosis:
Drug/alcohol abuse/dependence within the last 3 months of first recognition of impairment or delirium.
*Clinically significant deficits include moderate severity. Cognitive impairment in mild VCI is differentiated from major
(VaD) by not being clinically significant. y Definitions were agreed in VICCCS-1 and supported in VICCCS-2.
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AHA/ASA. Loss of independence in IADLs is the threshold
in VASCOG and DSM-5. In VICCCS-1, assessment of both
IADLs and ADLs was deemed necessary to determine
severity. Patients with PSD, SIVaD, and MID are also subca-
tegorized in VICCCS but not specified in AHA/ASA,
although subtypes in VASCOG include cortical-subcortical
and subcortical ischemic. The AHA/ASA category of “un-
stable VaMCI”, for cases that revert to normal from VaMCI,
was not supported by VICCCS respondents.
One of the main differences between VICCCS and AHA/
ASA is the VICCCS subcategorization of patients with co-
morbid pathologies, seen to be important, under the umbrella
term “mixed dementias” but with the types of pathologies
specified. Improvements in the accuracy of this would be
an important goal of any future operational diagnostic proto-
cols, for which research into biomarkers may be helpful [37].
The AHA/ASA does not delineate these subgroups of pa-
tients, with only the categories of “possible” VaD or VaMCI
allowing the inclusion of other phenotypes (e.g., evidence of
other neurodegenerative disorders). VASCOG criteria
encompass categories of multiple causation, including
VCD with concomitant AD (major or mild) and VCD with
additional pathology: for example, Lewy body disease.
In VICCCS, the use of probable and possible terms is
reserved for the strength of evidence to support diagnosis.
One such example of supportive evidence is a clear temporal
relationship between a vascular event and onset of cognitive
deficits in PSD, which is differentiated from other forms of
VCI by the onset of symptoms within 6 months of stroke.
Another is the imaging of CVD. VICCCS respondents
concluded that MRI is the gold standard for imaging. If
CT were the only means available, only a “probable” diag-
nosis could be made, and only a diagnosis of “possible” if
no imaging evidence were available. The recent STRIVE
imaging criteria for small-vessel disease [38] published after
the completion of our study, aligned with VICCCS’ concep-
tualization for SIVaD, warrant consideration in future
validations of VICCCS-2. VICCCS supports and expands
on the AHA/ASA guidance on patients with aphasia, in
whom assessment of IADLs/ADLs should be made when
possible, allowing diagnosis of “probable” with imaging ev-
idence or “possible” without it.4.2. Limitations and future work
The use of online Delphi surveys in VICCCS allowed
flexible and confidential participation among an unprece-
dented number of international participants over an extended
period [25,26,39]. The guidelines reflect considered opinion
because there was little participant attrition between rounds
(90%–97% of participants responding over rounds 2–6),
reflecting sustained engagement, with most topics
addressed over multiple rounds.Given the large number of respondents and their broad in-
terdisciplinarity, it is noteworthy that we achieved consensus
on most topics addressed in VICCCS. Reaching consensus
was most challenging for the definition of major VCI
(VaD), perhaps reflecting residual sensitivities associated
with this diagnosis and associated implications for health
and social care services. Consequently, specific thresholds
of severity of impairment were not established. VICCCS-1
concluded that subtyping of mild VCI may be worthwhile
but required more research [25], a view supported in a recent
study that highlighted the importance of harmonizing neuro-
psychological test score levels for defining impairment [40].
Inclusion of defined thresholds of severity of impairment
within the neuropsychological test battery and IADLs/
ADLs may help to guide the differentiation of VCI subtypes
in clinical settings. Support for the continued use of Mini–
Mental State Examination [41] may be surprising, given
that MoCA [42] has been shown to be an equivalent or
more sensitive test for the detection of VCI, ([43,44], for
example). It is noteworthy that only 23% of respondents
indicated use of the NINDS-CSN 5-minute protocol, (see
Supplementary Material), while NINDS-CSN endorsed the
full and the short MoCA. The use of biomarkers and ad-
vances in imaging criteria [38,45,46], including the use of
arterial spin–labeling MRI [47,48], may refine the
subtyping of mild and major VCI. Further work is needed
on imaging protocols, including measurement of gray
matter atrophy, cortical thinning or global atrophy in the
context of suspected VCI [49,50]. Given the presence of
vascular pathologies in apparent cognitively normal elderly
people, recent progress in establishing neuropathological
diagnostic criteria for assessing the likelihood that CVD
contributed to premortem cognitive impairment [51] is likely
to have an important role in the validation of future premor-
tem diagnostic approaches. Translational models and genetic
studies may provide further insight into the pathological
mechanisms and possible therapeutic targets for VCI [52].
A multimodal strategy for treatment of VCI, incorporating
both nonpharmacological therapies, such as transcranial
magnetic stimulation ([53], for review), and pharmacolog-
ical treatment, has been proposed [54].5. Conclusions
We present a consensus-based set of guidelines for diag-
nosing VCI, supported by a large multinational group of re-
searchers. VICCCS guidelines have drawn upon, critiqued,
expanded, and refined previous efforts. We hope that they
will be widely adopted, to improve consistency in diagnosis
and standardization in VCI research. This would allow better
comparison of findings across studies and facilitate large-
scale collaborative research on a group of diseases that
despite modest prevalence and considerable heterogeneity
have major societal impact.
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1. Systematic review: Criteria for diagnosis of vascular
cognitive impairment (VCI) were reviewed and
refined through several rounds of a multinational
Delphi survey, after PubMed search identified 15
articles (published before August 2010) proposing
diverse diagnostic criteria for diagnosis of multi-
infarct dementia; vascular dementia (VaD), subcor-
tical (ischemic) VaD, VCI, and vascular cognitive
disorders. The manuscript author lists identified
most of the study participants, and a Steering Group.
2. Interpretation: This survey yielded consensus-based
guidelines for the diagnosis of VCI that have drawn
upon and refined previous proposals. The high levels
of participation by the research community demon-
strate endorsement, and should promote widespread
adoption of the guidelines.
3. Future directions: Consensus research priorities
include: evidence-based studies to (i) determine
appropriate subdivision of mild VCI, and define
thresholds for severity of impairment; (ii) improve
phenotyping of concurrent pathology in mixed
dementias or psychiatric disorders that present with
cerebrovascular disease.
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